University of North Carolina at Chapel Hill-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2021

  1. A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

    Blood Cancer Journal

2014

  1. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

    British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477

2010

  1. International network of cancer genome projects

    Nature, Vol. 464, Núm. 7291, pp. 993-998